Physician profile
Lori Fortner
NPI 1982978532
$1,497.61
in general payments reported to CMS, 2019-2025
19 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $218 · 2023: $452 · 2024: $318 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.93 | 2021-2025 | |
| Pfizer INC. | $85.97 | 2021-2024 | |
| Glaxosmithkline, LLC. | $79.83 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $70.52 | 2023 | Auvelity |
| Abbott Laboratories | $59.32 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $58.54 | 2021-2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $44.05 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $36.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.15 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $25.50 | 2024 | Voquezna |
| Medtronic, INC. | $25.04 | 2021 | |
| Verona Pharma, INC. | $24.95 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.78 | 2024 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $23.05 | 2025 | Breztri |
| Astellas Pharma US INC | $20.62 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.53 | 2025 | Caplyta |
| Genentech USA, INC. | $19.77 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Fortner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.